摘要
乙型肝炎复发是乙型肝炎肝移植受者术后面临的常见问题之一。近年来,核苷(酸)类似物(NAs)的应用极大地降低了肝移植术后乙型肝炎复发率,但其长期应用也带来了诸如HBV耐药及肾功能损伤等弊端。富马酸替诺福韦酯(TDF)和富马酸丙酚替诺福韦(TAF)均属于治疗乙型肝炎的低耐药NAs,其在肝移植领域的临床应用显示出良好的疗效和耐受性,尤其是在单一NAs预防肝移植术后乙型肝炎复发方面,具有较好的应用前景。本文对TDF和TAF等新型NAs在乙型肝炎肝移植术后的最新应用进展作一综述。
Hepatitis B virus(HBV)reactivation is one of the common problems faced by HBV-related recipients after liver transplantation.Recently,the application of nucleos(t)ide analogues(NAs)has greatly reduced the recurrence rate of HBV after liver transplantation,and long-term medication has also brought many disadvantages,such as drug resistance,kidney damage.Tenofovir disoproxil fumarate(TDF)and tenofovir alafenamide fumarate(TAF)are both high genetic barrier NAs,and clinical applications show that they have good efficacy and tolerability,especially NAs monoprophylaxis have a good application prospect against HBV reactivation after liver transplantation.This article reviews the latest application progress of TDF and TAF after liver transplantation.
作者
翟慧敏
解曼
孔心涓
饶伟
Zhai Huimin;Xie Man;Kong Xinjuan;Rao Wei(Department of Gastroenterology;Center for Organ Transplantation,Liver Disease Center,Institute of Transplantation Science,Qingdao University,the Affiliated Hospital of Qingdao University,Qingdao 266000,China)
出处
《中华移植杂志（电子版）》
CAS
2021年第5期302-306,共5页
Chinese Journal of Transplantation(Electronic Edition)
基金
青岛大学医学部“临床医学+X”科研课题(2017223)。
